Nanoparticle-based delivery of small-molecule ferroptosis inducers primarily focuses on system Xc− inhibitors (e.g., erastins, sulfasalazine, sorafenib) and GPX4 inhibitors (such as RSL3 and altretamine), as well as approaches inducing GPX4 degradation (e.g., FIN56) and GSH depletion (e.g., buthionine sulfoximine, DPI2), offering potential therapeutic avenues for cancer [18]. The gene discussed is GPX4; the disease is cancer.